Discovery of a novel HCV helicase inhibitor by a de novo drug design approach.
暂无分享,去创建一个
Dimitrios Vlachakis | Colin Berry | Andrea Brancale | Antonio Coluccia | Pieter Leyssen | Johan Neyts | A. Coluccia | A. Brancale | J. Neyts | D. Vlachakis | P. Leyssen | Sahar Kandil | C. Berry | Sonia Biondaro | Anna-Claire Cummins | Sahar B Kandil | S. Biondaro | A. Cummins
[1] Michael Hedrick,et al. Total Synthesis of Distamycin A and 2640 Analogues: A Solution-Phase Combinatorial Approach to the Discovery of New, Bioactive DNA Binding Agents and Development of a Rapid, High-Throughput Screen for Determining Relative DNA Binding Affinity or DNA Binding Sequence Selectivity , 2000 .
[2] J P Griffith,et al. Hepatitis C virus NS3 RNA helicase domain with a bound oligonucleotide: the crystal structure provides insights into the mode of unwinding. , 1998, Structure.
[3] E. Novellino,et al. Specific targeting of hepatitis C virus NS3 RNA helicase. Discovery of the potent and selective competitive nucleotide-mimicking inhibitor QU663. , 2005, Biochemistry.
[4] M. Alaoui-Ismaili,et al. A novel high throughput screening assay for HCV NS3 helicase activity. , 2000, Antiviral research.
[5] David N. Frick,et al. Two Novel Conserved Motifs in the Hepatitis C Virus NS3 Protein Critical for Helicase Action* , 2003, Journal of Biological Chemistry.
[6] A. Fattom,et al. Ring-expanded ("fat") nucleoside and nucleotide analogues exhibit potent in vitro activity against flaviviridae NTPases/helicases, including those of the West Nile virus, hepatitis C virus, and Japanese encephalitis virus. , 2003, Journal of medicinal chemistry.
[7] N. Hayashi,et al. Antiviral therapy for chronic hepatitis C: past, present, and future , 2005, Journal of Gastroenterology.
[8] V. Soriano,et al. New therapies for hepatitis C virus infection. , 2009, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[9] E. Chinje,et al. Synthesis of N-benzyl- and N-phenyl-2-amino-4,5-dihydrothiazoles and thioureas and evaluation as modulators of the isoforms of nitric oxide synthase. , 2003, Bioorganic & medicinal chemistry.
[10] P. Herdewijn,et al. Comparative In Vitro Anti-Hepatitis C Virus Activities of a Selected Series of Polymerase, Protease, and Helicase Inhibitors , 2008, Antimicrobial Agents and Chemotherapy.
[11] H. Blum,et al. Molecular Virology of Hepatitis C Virus (HCV): 2006 Update , 2006, International journal of medical sciences.
[12] Gisbert Schneider,et al. Computer-based de novo design of drug-like molecules , 2005, Nature Reviews Drug Discovery.
[13] David N. Frick,et al. Hepatitis C Virus Subgenomic Replicon Requires an Active NS3 RNA Helicase , 2006, Journal of Virology.
[14] Jane Collier,et al. Development of novel treatments for hepatitis C. , 2009, The Lancet. Infectious diseases.
[15] Luhua Lai,et al. LigBuilder: A Multi-Purpose Program for Structure-Based Drug Design , 2000 .